Daniel Fronk, MD
Cardiovascular Disease · Farmington, UTNPI 1639515869
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $8,533 of the $12,754 with a category attached, or 66.9%. Medtronic accounts for 63.1% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2023 at $8,642 and has fallen 76.0% since, to $2,074 in 2025.
Across 94 payments — averaging $135.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$8K
- Endologix LLC$2K
- Abbott$1K
- Edwards Lifesciences$649
- Boston Scientific$405
- Inari Medical, Inc.$212
- plus $568 from 15 others
What the payments were for
- Travel & lodging$8,53367%
- Food & beverage$4,22133%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 34 | $8,049 |
| Endologix LLC | 10 | $1,822 |
| Abbott | 5 | $1,048 |
| Edwards Lifesciences | 3 | $649 |
| Boston Scientific | 13 | $405 |
| Inari Medical, Inc. | 2 | $212 |
| Novartis | 5 | $103 |
| Cardiovascular Systems Inc. | 3 | $61 |
| Philips North America LLC | 3 | $45 |
| Teleflex LLC | 3 | $44 |
| Baxter Healthcare | 1 | $44 |
| Cvrx, Inc. | 2 | $41 |
| E.r. Squibb & Sons, L.L.C. | 2 | $40 |
| W. L. Gore & Associates, Inc. | 1 | $34 |
| Terumo Medical Corporation | 1 | $32 |
| Abiomed | 1 | $29 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
| Shockwave Medical, Inc | 1 | $22 |
| Boehringer Ingelheim | 1 | $20 |
| Stryker | 1 | $18 |
| Livanova USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,754 in reported general payments places this provider in the 80th percentile of 131 cardiovascular disease providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 134 | $135,501 |
| XareltoRivaroxaban | 96 | $120,586 |
| BrilintaTicagrelor | 52 | $37,465 |
| FarxigaDapagliflozin Propanediol | 20 | $30,260 |
| Repatha SureclickEvolocumab | 29 | $17,381 |
| EntrestoSacubitril/Valsartan | 11 | $16,554 |
| Bumetanide | 24 | $2,098 |
| Rosuvastatin Calcium | 163 | $1,993 |
| Metoprolol Succinate | 123 | $1,958 |
| Ranolazine ErRanolazine | 25 | $1,709 |
| Amiodarone Hcl | 108 | $1,611 |
| Prasugrel Hcl | 21 | $1,400 |
| Atorvastatin Calcium | 146 | $1,320 |
| ClopidogrelClopidogrel Bisulfate | 134 | $1,239 |
| Losartan Potassium | 120 | $1,132 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $103 | $16,55411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 131 cardiovascular disease providers in Utah.
Other cardiovascular disease in Farmington
- Christopher KimFarmington$36K
- John RyanSalt Lake City$1.4M
- Robert FowlesSalt Lake City$611K
- Brian WhisenantMurray$416K
- Andrew BehuninDraper$192K
- Jeffrey OsbornSalt Lake City$69K
- James FangSalt Lake City$67K
- Joseph MuhlesteinMurray$65K
- Hannah RaaschSalt Lake City$62K
- Divya Ratan VermaMurray$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.